MLYS: SEC Form 3 filed by Mineralys Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for MLYS
Across the 29 sessions after earlier MLYS headlines, the stock closed higher 12 times and lower 17 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MLYS | SPY |
|---|---|---|---|
| Oct 20, 2026 | Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats | +3.2% | +0.3% |
| Oct 12, 2026 | UBS initiated coverage on Mineralys Therapeutics with a new price target | -4.9% | -0.1% |
| Oct 9, 2026 | Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 | +4.4% | +0.6% |
| Oct 5, 2026 | Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 | -1.4% | +0.7% |
| Oct 2, 2026 | Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 | -0.4% | +0.7% |
| Sep 30, 2026 | Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | +2.7% | -0.2% |
Keep researching MLYS
- MLYS insider tradesEvery buy and sale reported by Mineralys Therapeutics Inc. officers, directors and large holders.
- What is Form 3?The initial SEC statement of beneficial ownership filed by a company's officers, directors and 10% holders when they first become insiders.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- MLYS earnings historyPast Mineralys Therapeutics Inc. earnings releases, newest first.
- MLYS financial statementsRevenue, profit, cash flow and balance sheet from Mineralys Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
MLYS
Mineralys Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2023
Get push alerts for MLYS
Full MLYS profile on Quantisnow Follow MLYS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time